Published in Radiother Oncol on August 10, 2005
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest (2009) 3.01
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68
The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal (2014) 2.26
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2009) 2.26
Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells (2010) 1.78
Imaging oxygenation of human tumours. Eur Radiol (2006) 1.78
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 1.74
Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.64
Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and long-term outcomes in patients with locally advanced rectal cancers. Colorectal Dis (2013) 1.60
Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity. Radiat Res (2015) 1.53
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys (2007) 1.50
Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med (2009) 1.50
Time-gated Cherenkov emission spectroscopy from linear accelerator irradiation of tissue phantoms. Opt Lett (2012) 1.44
Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells. PLoS One (2014) 1.42
Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol (2011) 1.35
Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer (2011) 1.34
FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging (2006) 1.27
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging (2009) 1.23
Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol (2008) 1.23
Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis (2014) 1.22
Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res (2010) 1.19
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys (2009) 1.16
Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle (2013) 1.14
Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys (2010) 1.13
Solving the puzzle of metastasis: the evolution of cell migration in neoplasms. PLoS One (2011) 1.12
Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med (2009) 1.12
HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer (2010) 1.08
Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer (2007) 1.07
Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging (2008) 1.07
Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer (2017) 1.07
The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med (2010) 1.06
Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer. J Oncol (2009) 1.06
An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response. Phys Med Biol (2008) 1.06
Quantitative oxygenation venography from MRI phase. Magn Reson Med (2013) 1.04
On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Phys Med Biol (2009) 1.04
Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. Radiat Oncol (2014) 1.03
Quantitative optical spectroscopy can identify long-term local tumor control in irradiated murine head and neck xenografts. J Biomed Opt (2009) 1.03
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther (2010) 1.03
An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in advanced head-and-neck cancer. Med Phys (2012) 1.02
Gene expression and hypoxia in breast cancer. Genome Med (2011) 1.02
Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging (2008) 1.02
Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol (2011) 1.02
Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer (2006) 1.01
Near infrared luminescent oxygen nanosensors with nanoparticle matrix tailored sensitivity. Anal Chem (2010) 0.99
Non-invasive imaging of angiogenesis in head and neck squamous cell carcinoma. Angiogenesis (2010) 0.99
Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol (2012) 0.99
Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis (2009) 0.99
New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol (2008) 0.98
Radiation oncology in the era of precision medicine. Nat Rev Cancer (2016) 0.97
EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle (2013) 0.97
Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol (2011) 0.97
Feasibility of dose painting using volumetric modulated arc optimization and delivery. Acta Oncol (2010) 0.96
TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer (2012) 0.96
Recent advances in image-guided radiotherapy for head and neck carcinoma. J Oncol (2009) 0.96
In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs. Radiat Oncol (2011) 0.95
Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol (2014) 0.95
Lifetime-based photoacoustic oxygen sensing in vivo. J Biomed Opt (2012) 0.95
In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res (2014) 0.94
Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 0.94
Theranostic oxygen delivery using ultrasound and microbubbles. Theranostics (2012) 0.94
Monitoring of hemodynamic changes induced in the healthy breast through inspired gas stimuli with MR-guided diffuse optical imaging. Med Phys (2010) 0.94
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. Clin Cancer Res (2013) 0.94
Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev (2008) 0.94
Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res (2011) 0.93
A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging (2014) 0.93
The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 0.93
HypoxamiRs and cancer: from biology to targeted therapy. Antioxid Redox Signal (2013) 0.92
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol (2009) 0.92
Tumor hypoxia as a driving force in genetic instability. Genome Integr (2013) 0.92
PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. Proc Natl Acad Sci U S A (2013) 0.92
Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions. PLoS One (2014) 0.91
Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol (2016) 0.91
Quantitative Cherenkov emission spectroscopy for tissue oxygenation assessment. Opt Express (2012) 0.90
Old but new methods in radiation oncology: hyperbaric oxygen therapy. Int J Clin Oncol (2013) 0.90
Targeted molecular imaging in oncology: focus on radiation therapy. Semin Radiat Oncol (2008) 0.89
Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity. Strahlenther Onkol (2012) 0.89
Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nucl Med Biol (2008) 0.88
Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy. Radiother Oncol (2008) 0.86
The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res (2016) 0.86
Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer. Br J Radiol (2011) 0.86
Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiat Oncol (2013) 0.86
Retracted PET imaging of tumour hypoxia. Cancer Imaging (2006) 0.86
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Front Oncol (2016) 0.85
In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2008) 0.85
Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis. J Cereb Blood Flow Metab (2014) 0.85
Molecular basis of 'hypoxic' breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling. Radiat Oncol (2013) 0.85
Photoacoustic monitoring of tumor and normal tissue response to radiation. Sci Rep (2016) 0.84
Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion. Int J Radiat Oncol Biol Phys (2015) 0.84
Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo. Radiother Oncol (2012) 0.84
Mitochondrial DNA mutations in head and neck cancer are infrequent and lack prognostic utility. Br J Cancer (2011) 0.84
Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors. Radiat Oncol (2012) 0.84
Molecular and cellular processes underlying the hallmarks of head and neck cancer. Eur Arch Otorhinolaryngol (2012) 0.84
Rapid determination of oxygen saturation and vascularity for cancer detection. PLoS One (2013) 0.83
Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcome. Head Neck (2010) 0.83
PET imaging biomarkers in head and neck cancer. Eur J Nucl Med Mol Imaging (2015) 0.83
Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp Mol Pathol (2011) 0.83
Imaging tumor hypoxia to advance radiation oncology. Antioxid Redox Signal (2014) 0.83
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (2006) 6.67
Analyses of pig genomes provide insight into porcine demography and evolution. Nature (2012) 5.58
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 3.70
Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol (2007) 3.39
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol (2007) 3.06
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol (2011) 3.04
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol (2008) 2.85
Isolation of novel ultramicrobacteria classified as actinobacteria from five freshwater habitats in Europe and Asia. Appl Environ Microbiol (2003) 2.50
Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. Int J Radiat Oncol Biol Phys (2006) 2.48
Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys (2012) 2.41
Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol (2003) 2.32
Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol (2008) 2.28
Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol (2003) 2.26
The filtration-acclimatization method for isolation of an important fraction of the not readily cultivable bacteria. J Microbiol Methods (2004) 2.21
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys (2007) 2.21
In vitro RBE-LET dependence for multiple particle types. Acta Oncol (2011) 2.18
A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol (2008) 2.15
Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol (2010) 2.12
Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol (2006) 2.00
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res (2003) 1.96
Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys (2007) 1.91
Impact of delay on diagnosis and treatment of primary lung cancer. Acta Oncol (2002) 1.91
Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid (2009) 1.90
Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiat Oncol Biol Phys (2006) 1.88
Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol (2013) 1.78
TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol (2005) 1.78
Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol (2005) 1.77
Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol (2006) 1.76
Does amifostine have a role in chemoradiation treatment? Lancet Oncol (2003) 1.73
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys (2010) 1.68
The role of postoperative radiotherapy for the treatment of gangliogliomas. Cancer (2010) 1.67
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.66
The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys (2010) 1.65
Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis. Int J Radiat Oncol Biol Phys (2008) 1.63
Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANCA. Acta Oncol (2006) 1.63
A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.59
Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol (2012) 1.57
Radiotherapy alone for primary Merkel cell carcinoma. Arch Dermatol (2003) 1.55
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol (2009) 1.55
Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas. Acta Ophthalmol Scand (2004) 1.54
Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother Oncol (2013) 1.54
Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol (2014) 1.54
L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.50
Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys (2004) 1.50
Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck (2008) 1.49
High diversity of the 'Spumella-like' flagellates: an investigation based on the SSU rRNA gene sequences of isolates from habitats located in six different geographic regions. Environ Microbiol (2005) 1.49
Disease presentation and treatment outcome in very young patients with brain metastases from lung cancer. Onkologie (2008) 1.48
Supraglottic carcinoma: patterns of failure and salvage treatment after curatively intended radiotherapy in 410 consecutive patients. Int J Radiat Oncol Biol Phys (2002) 1.46
Association between research sponsorship and study outcome in plastic surgery literature. Ann Plast Surg (2009) 1.45
Calcium management after thyroidectomy: a simple and cost-effective method. Otolaryngol Head Neck Surg (2012) 1.45
Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture. Int J Radiat Oncol Biol Phys (2010) 1.44
Strain-specific differences in the grazing sensitivities of closely related ultramicrobacteria affiliated with the Polynucleobacter cluster. Appl Environ Microbiol (2004) 1.44
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res (2009) 1.43
Automatic segmentation of pelvic structures from magnetic resonance images for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.43
Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys (2004) 1.41
NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw (2008) 1.41
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol (2010) 1.40
Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Radiat Oncol Biol Phys (2005) 1.38
Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol (2006) 1.38
A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol (2012) 1.35
Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. Cancer Res (2006) 1.34
Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev (2006) 1.34
Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res (2011) 1.33
Positron emission tomography for radiation treatment planning. Strahlenther Onkol (2005) 1.33
Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer (2008) 1.32
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
Evaluation of objective measures of smoking status--a prospective clinical study in a group of head and neck cancer patients treated with radiotherapy. Acta Oncol (2003) 1.30
Differences in the kinetics of gamma-H2AX fluorescence decay after exposure to low and high LET radiation. Int J Radiat Biol (2010) 1.30
Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol (2002) 1.29
HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol (2009) 1.28
Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol (2010) 1.28
The first score predicting overall survival in patients with metastatic spinal cord compression. Cancer (2008) 1.28
Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology (Berl) (2006) 1.27
Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. Radiother Oncol (2004) 1.27
Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys (2010) 1.27
Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys (2011) 1.26
Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2005) 1.24
Molecular therapy in head and neck oncology. Nat Rev Clin Oncol (2009) 1.24
FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol (2012) 1.24
Quality of life in long-term survivors of oropharynx carcinoma. Int J Radiat Oncol Biol Phys (2002) 1.23
How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol (2003) 1.23
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol (2008) 1.23
Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys (2007) 1.22
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. Endocr Pract (2015) 1.22
Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol (2008) 1.21
Biologic basis for combining drugs with radiation. Semin Radiat Oncol (2006) 1.20
Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol (2004) 1.20
Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother Oncol (2011) 1.19
Structure of transfer RNAs: similarity and variability. Wiley Interdiscip Rev RNA (2011) 1.18
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys (2005) 1.18